Ghost Tree Capital’s Arcturus Therapeutics ARCT Stock Holding History

Ghost Tree Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-71,429	Closed	-$1.05M	–	69
2016 Q4	$1.05M	Sell	71,429 -21,428	-23%	-$320K	0.25%	61
2016 Q3	$1.61M	Buy	92,857 +50,000	+117%	+$1.62M	0.26%	74
2016 Q2	$1.35M	Hold	42,857	–	–	0.39%	50
2016 Q1	$1.14M	Sell	42,857 -28,572	-40%	-$967K	0.64%	41
2015 Q4	$3.14M	Sell	71,429 -26,994	-27%	-$1.22M	1.29%	31
2015 Q3	$4.16M	Buy	98,423 +12,709	+15%	+$669K	1.87%	19
2015 Q2	$3.92M	Sell	85,714 -28,572	-25%	-$1.31M	1.27%	37
2015 Q1	$4.5M	Buy	+114,286	New	+$5.03M	1.62%	20

Other funds holding ARCT

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Ghost Tree Capital's ARCT Position: Q1 2017 in Review

Ghost Tree Capital sold out of Arcturus Therapeutics (ARCT) in Q1 2017, closing a stake of 71,429 shares — an estimated $1.05M sold.

Ghost Tree Capital first reported a position in ARCT in Q1 2015 and held it in 8 quarters. The position peaked at $4.5M in Q1 2015. 33 funds tracked by Wall St. Rank hold ARCT as of Q1 2017.

Ghost Tree Capital reported no remaining Arcturus Therapeutics position as of Q1 2017 after selling out during the quarter.
Ghost Tree Capital sold 71,429 Arcturus Therapeutics shares in Q1 2017, an estimated $1.05M.
Ghost Tree Capital first reported a position in Arcturus Therapeutics in Q1 2015 and held it in 8 quarters.
Ghost Tree Capital's Arcturus Therapeutics position peaked at $4.5M in Q1 2015.
33 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2017.

Based on Ghost Tree Capital's 13F filing for Q1 2017, filed 15 May 2017.